FMP
Allena Pharmaceuticals, Inc.
ALNA
NASDAQ
Inactive Equity
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
0.075 USD
0.0023000017 (3.07%)
About
ceo
Dr. Louis Brenner
sector
Healthcare
industry
Biotechnology
website
https://www.allenapharma.com
exchange
NASDAQ
Description
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
CIK
0001624658
ISIN
US0181191075
CUSIP
018119107
Address
1 Newton Executive Park Ste 20...
Phone
16174674577
Country
US
Employee
12
IPO Date
Nov 2, 2017
Key Executives
